View in EDS HTML Full Text PDF Full Text

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INT-787, a Novel Farnesoid X Receptor Agonist, in Healthy Volunteers: A Phase 1 Trial.

Saved in:
Bibliographic Details
Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INT-787, a Novel Farnesoid X Receptor Agonist, in Healthy Volunteers: A Phase 1 Trial.
Authors: Capozza T; Intercept Pharmaceuticals, Inc, Morristown, New Jersey, USA., Burkey J; Intercept Pharmaceuticals, Inc, Morristown, New Jersey, USA., Van De Wetering J; ICON, Groningen, the Netherlands., Kerb R; ICON, Mannheim, Germany., Callahan J; Intercept Pharmaceuticals, Inc, Morristown, New Jersey, USA., Kryzhanovskaya L; Intercept Pharmaceuticals, Inc, Morristown, New Jersey, USA., Erickson M; Intercept Pharmaceuticals, Inc, Morristown, New Jersey, USA.
Source: Clinical and translational science [Clin Transl Sci] 2025 May; Vol. 18 (5), pp. e70229.
Publication Type: Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial
Journal Info: Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40304628
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INT-787, a Novel Farnesoid X Receptor Agonist, in Healthy Volunteers: A Phase 1 Trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Capozza+T%22">Capozza T</searchLink>; Intercept Pharmaceuticals, Inc, Morristown, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Burkey+J%22">Burkey J</searchLink>; Intercept Pharmaceuticals, Inc, Morristown, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Van+De+Wetering+J%22">Van De Wetering J</searchLink>; ICON, Groningen, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Kerb+R%22">Kerb R</searchLink>; ICON, Mannheim, Germany.<br /><searchLink fieldCode="AU" term="%22Callahan+J%22">Callahan J</searchLink>; Intercept Pharmaceuticals, Inc, Morristown, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Kryzhanovskaya+L%22">Kryzhanovskaya L</searchLink>; Intercept Pharmaceuticals, Inc, Morristown, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Erickson+M%22">Erickson M</searchLink>; Intercept Pharmaceuticals, Inc, Morristown, New Jersey, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101474067%22">Clinical and translational science</searchLink> [Clin Transl Sci] 2025 May; Vol. 18 (5), pp. e70229.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22WileyBlackwell+Pub%22">WileyBlackwell Pub </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101474067 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1752-8062 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217528054%22">17528054 </searchLink><i>NLM ISO Abbreviation: </i>Clin Transl Sci <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40304628
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/cts.70229
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e70229
    Titles:
      – TitleFull: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INT-787, a Novel Farnesoid X Receptor Agonist, in Healthy Volunteers: A Phase 1 Trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Capozza T
      – PersonEntity:
          Name:
            NameFull: Burkey J
      – PersonEntity:
          Name:
            NameFull: Van De Wetering J
      – PersonEntity:
          Name:
            NameFull: Kerb R
      – PersonEntity:
          Name:
            NameFull: Callahan J
      – PersonEntity:
          Name:
            NameFull: Kryzhanovskaya L
      – PersonEntity:
          Name:
            NameFull: Erickson M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2025 May
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1752-8062
          Numbering:
            – Type: volume
              Value: 18
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Clinical and translational science
              Type: main
ResultId 1